592 related articles for article (PubMed ID: 33340426)
1. Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.
Rundquist S; Sachs MC; Eriksson C; Olén O; Montgomery S; Halfvarson J;
Aliment Pharmacol Ther; 2021 Feb; 53(4):471-483. PubMed ID: 33340426
[TBL] [Abstract][Full Text] [Related]
2. Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease.
Kirchgesner J; Desai RJ; Beaugerie L; Schneeweiss S; Kim SC
Clin Gastroenterol Hepatol; 2022 Feb; 20(2):314-324.e16. PubMed ID: 33387667
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Vedolizumab Versus Tumor Necrosis Factor α Antagonists in an Elderly IBD Population: A Single Institution Retrospective Experience.
Pabla BS; Alex Wiles C; Slaughter JC; Scoville EA; Dalal RL; Beaulieu DB; Schwartz DA; Horst SN
Dig Dis Sci; 2022 Jul; 67(7):3129-3137. PubMed ID: 34268660
[TBL] [Abstract][Full Text] [Related]
4. Systematic Review and Meta-Analysis: Preoperative Vedolizumab and Postoperative Complications in Patients with IBD.
Moosvi Z; Duong JT; Bechtold ML; Nguyen DL
South Med J; 2021 Feb; 114(2):98-105. PubMed ID: 33537791
[TBL] [Abstract][Full Text] [Related]
5. Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience.
Erdoğan Ç; Yeşil B; Bacaksız F; Arı D; Gökbulut V; Yüksel M; Özderin Özin Y; Kayaçetin E
Turk J Gastroenterol; 2022 Oct; 33(10):831-837. PubMed ID: 35946879
[TBL] [Abstract][Full Text] [Related]
6. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Guardiola J; Jahnsen J; Lees C; Louis E; Lukáš M; Reinisch W; Roblin X; Jang M; Byun HG; Kim DH; Lee SJ; Atreya R
BMC Gastroenterol; 2022 Jun; 22(1):291. PubMed ID: 35676620
[TBL] [Abstract][Full Text] [Related]
8. Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-Tumor Necrosis Factor Agents in Older Adults.
Kochar B; Pate V; Kappelman MD; Long MD; Ananthakrishnan AN; Chan AT; Sandler RS
Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1299-1305.e5. PubMed ID: 34481954
[TBL] [Abstract][Full Text] [Related]
9. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A
J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study.
Pugliese D; Privitera G; Crispino F; Mezzina N; Castiglione F; Fiorino G; Laterza L; Viola A; Bertani L; Caprioli F; Cappello M; Barberio B; Ricci C; Balestrieri P; Daperno M; Pluchino D; Rizzello F; Scribano ML; Sablich R; Pastorelli L; Manguso F; Variola A; Di Sario A; Grossi L; Armuzzi A;
Aliment Pharmacol Ther; 2022 Jul; 56(1):95-109. PubMed ID: 35876062
[TBL] [Abstract][Full Text] [Related]
11. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
Eriksson C; Marsal J; Bergemalm D; Vigren L; Björk J; Eberhardson M; Karling P; Söderman C; ; Myrelid P; Cao Y; Sjöberg D; Thörn M; Karlén P; Hertervig E; Strid H; Ludvigsson JF; Almer S; Halfvarson J
Scand J Gastroenterol; 2017; 52(6-7):722-729. PubMed ID: 28362144
[TBL] [Abstract][Full Text] [Related]
12. Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease.
Eriksson C; Söderling J; Karlqvist S; Bröms G; Everhov ÅH; Bergemalm D; Ludvigsson JF; ; Olén O; Halfvarson J
Dig Dis Sci; 2023 Jul; 68(7):3119-3128. PubMed ID: 36929241
[TBL] [Abstract][Full Text] [Related]
13. Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN.
Ledder O; Assa A; Levine A; Escher JC; de Ridder L; Ruemmele F; Shah N; Shaoul R; Wolters VM; Rodrigues A; Uhlig HH; Posovszky C; Kolho KL; Jakobsen C; Cohen S; Shouval DS; de Meij T; Martin-de-Carpi J; Richmond L; Bronsky J; Friedman M; Turner D
J Crohns Colitis; 2017 Oct; 11(10):1230-1237. PubMed ID: 28605483
[TBL] [Abstract][Full Text] [Related]
14. Second-Line Biologic Therapy Following Tumor Necrosis Factor Antagonist Failure: A Real-World Propensity Score-Weighted Analysis.
Ibing S; Cho JH; Böttinger EP; Ungaro RC
Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2629-2638. PubMed ID: 36787837
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn's disease in patients with prior failure of anti-tumour necrosis factor treatment.
Hyun HK; Zhang HS; Yu J; Kang EA; Park J; Park SJ; Park JJ; Kim TI; Kim WH; Cheon JH
BMC Gastroenterol; 2022 Mar; 22(1):143. PubMed ID: 35346063
[TBL] [Abstract][Full Text] [Related]
16. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
[TBL] [Abstract][Full Text] [Related]
17. Mucosal Eosinophilia Is an Independent Predictor of Vedolizumab Efficacy in Inflammatory Bowel Diseases.
Kim EM; Randall C; Betancourt R; Keene S; Lilly A; Fowler M; Dellon ES; Herfarth HH
Inflamm Bowel Dis; 2020 Jul; 26(8):1232-1238. PubMed ID: 31633167
[TBL] [Abstract][Full Text] [Related]
18. Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis.
Lukin D; Faleck D; Xu R; Zhang Y; Weiss A; Aniwan S; Kadire S; Tran G; Rahal M; Winters A; Chablaney S; Koliani-Pace JL; Meserve J; Campbell JP; Kochhar G; Bohm M; Varma S; Fischer M; Boland B; Singh S; Hirten R; Ungaro R; Lasch K; Shmidt E; Jairath V; Hudesman D; Chang S; Swaminath A; Shen B; Kane S; Loftus EV; Sands BE; Colombel JF; Siegel CA; Sandborn WJ; Dulai PS
Clin Gastroenterol Hepatol; 2022 Jan; 20(1):126-135. PubMed ID: 33039584
[TBL] [Abstract][Full Text] [Related]
19. Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease - A nationwide Hungarian cohort study.
Bor R; Fábián A; Matuz M; Szepes Z; Farkas K; Miheller P; Szamosi T; Vincze Á; Rutka M; Szántó K; Bálint A; Nagy F; Milassin Á; Tóth T; Zsigmond F; Bajor J; Müllner K; Lakner L; Papp M; Salamon Á; Horváth G; Sarang K; Schäfer E; Sarlós P; Palatka K; Molnár T
Expert Opin Biol Ther; 2020 Feb; 20(2):205-213. PubMed ID: 31782939
[No Abstract] [Full Text] [Related]
20. Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients.
Verstockt B; Mertens E; Dreesen E; Outtier A; Noman M; Tops S; Schops G; Van Assche G; Vermeire S; Gils A; Ferrante M
J Crohns Colitis; 2020 Mar; 14(3):332-341. PubMed ID: 31504343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]